ArticleFrontiers in veterinary science2025
Morphological, phenotypical and molecular characterization of canine lymphomas with dual T- and B-cell markers expression.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recent investigations have identified rare, phenotypically complex lymphoma variants, including cases exhibiting concurrent expression of T- and B-cell markers. These atypical presentations suggest perturbations in lymphoid differentiation programs or clonal evolution, necessitating more sophisticated diagnostic approaches. The concurrent expression of CD3 and CD20 in canine lymphomas represents a particularly compelling phenomenon documented across various anatomical sites. Molecular diagnostics, particularly PCR for Antigen Receptor Rearrangements (PARR), have provided crucial insights into these phenotypically complex cases, revealing concurrent clonal rearrangements of both TCRγ and IgH in selected cases, further challenging traditional classification paradigms. Methods: Here, we report 33 cases of canine double-positive lymphoma, retrieved with a retrospective analysis of the MyLAV Diagnostic Laboratory electronic database. Specifically, we report results of an integrated approach combining WHO-based morphological classification, comprehensive immunohistochemical immunophenotyping with T-cell (CD3 and CD5) and B-cell markers (CD20 and PAX5), and PARR analysis. Results: The skin, oral/nasal mucosa and mucocutaneous junction were the most commonly affected sites, accounting for 24 cases (72.7%). All cases stained positive for CD3 and CD20 (100%), 32 (97%) for CD5, and only 12 (36.4%) for PAX5. Aberrant cytoplasmic localization of CD20 was found in 29 (87.9%) cases. Molecular analysis revealed rearrangement signals of TCR gene in 23 of 33 cases (69.7%) and of CBmajor or CBminor gene in 9 (27.3%). Discussion: The findings emphasize that while immunohistochemistry remains a fundamental diagnostic tool, it may be insufficient in isolation for definitive lineage determination in these cases. PARR analysis emerges as an essential complementary technique for distinguishing between aberrant marker expression and true biphenotypic differentiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.